Barisa ¿d T Cell Cancer Immunotherapy

Evidence-Based Perspectives for Clinical Translation
1. Auflage 2024
ISBN: 978-0-443-21767-8
Verlag: Elsevier Science & Techn.
Format: PDF
Kopierschutz: 1 - PDF Watermark

E-Book, Englisch, 286 Seiten

Reihe: Breaking Tolerance to Anti-Cancer Cell-Mediated Immunotherapy

?? T Cell Cancer Immunotherapy: Evidence-Based Perspectives for Clinical Translation sets out and critically discusses the current clinical and relevant preclinical ?? T cell immunotherapy landscape.In five chapters, field experts discuss the challenges facing ?? T cell oncoimmunotherapy, propose solutions, and map next steps.Particular attention is given to summarizing our understanding of the complex, translationally relevant human ?? T cell biology, the evidence basis for designing ?? T cell combination trials and data-driven perspectives on what is known-and what isn't-about ?? T cell therapeutic persistence. Various perspectives are provided on how issues of cytotoxic effector function, functional exhaustion, and cytokine addiction can be mitigated using gene engineering.A chapter is dedicated to the systematic review of all ?? T cell immunotherapy trials to date, and the cell therapy products that were used in these trials. The final chapter discusses allograft persistence-enhancement techniques in the context of ?? T cell therapy, covering lymphodepleting chemotherapy and synthetic stealth engineering.?? T Cell Cancer Immunotherapy: Evidence-Based Perspectives for Clinical Translation gives an updated and comprehensive insight into the current state of ??T cell immunotherapy, which is of interest to existing translational ?? T cell specialists, the proliferating range of academic scientists and commercial scientists entering the field, as well as clinicians who may encounter ?? T cell immunotherapy in the clinic, or are wishing to familiarize themselves with noncanonical lymphocyte immunotherapy. - Summarizes the cutting edge of oncology-relevant ?? T cell immunobiology - Lays out clinical successes and failures to date - Addresses the possible advantage of combining ?? T cell-based immunotherapy with conventional chemotherapy or checkpoint blockers - Provides an up-to-date and well-rounded discussion of a translationally, commercially, and scientifically relevant field

Autoren/Hrsg.

Barisa, Marta